Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

246.80 -3.93 (-1.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
The Latest Analyst Ratings For Insulet
Via Benzinga
Peering Into Insulet's Recent Short Interest
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Stocks On Track For Weekly Losses Despite Midday Gains
The Dow Jones Industrial Average, Nasdaq Composite, and S&P 500 Index are attempting to pare this morning's losses as they move into positive territory for the afternoon. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Today
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Insulet
Via Benzinga
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulet reported a Q2 adjusted EPS of $0.55, slightly missing estimates but showing strong sales growth of 23.2% year-over-year, driven by Omnipod revenue. The company raised its 2024 revenue guidance,... 
Via Benzinga
PODD Stock Earnings: Insulet Misses EPS, Beats Revenue for Q2 2024
PODD stock results show that Insulet missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
Via Benzinga
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the... 
Via Benzinga
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Why INSULET CORP (NASDAQ:PODD) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
(PODD) - Analyzing Insulet's Short Interest
Via Benzinga
Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?
Insulet Corporation shares are rising after the company reported stronger-than-expected second-quarter revenue, driven by high demand for Omnipod 5 and a raised full-year revenue outlook. 
Via Benzinga
Insulet Reports Preliminary Second Quarter 2024 Revenue Results
From Insulet Corporation
Via Business Wire
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Insulet Corporation
Via Business Wire
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD), a strong growth stock, setting up for a breakout. 
Via Chartmill
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking Into Insulet's Recent Short Interest
Via Benzinga
Where Insulet Stands With Analysts
Via Benzinga
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
From Insulet Corporation
Via Business Wire
The 3 Best Diabetes Stocks to Buy in June 2024
There's less fear now about weight-loss drugs reducing the need for diabetes devices. Here are three diabetes stocks to buy. 
Via InvestorPlace
7 Stocks That Could Safely 10X by 2030
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
Via InvestorPlace
Insulet to Present at the Jefferies Global Healthcare Conference
From Insulet Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.